Shanghai Junshi Biosciences Co Ltd

688180

Company Profile

  • Business description

    Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.

  • Contact

    No. 987 Cai Lun Road
    Level 4, China (Shanghai) Pilot Free Trade Zone
    Shanghai
    CHN

    https://www.junshipharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    2,903

Stocks News & Analysis

stocks

Avoid this overvalued ASX healthcare share

Expensive healthcare share limited by its core addressable market.
stocks

AI driving growth for ASX tech share

ASX tech share raises funds to facilitate customer AI spend.
stocks

OpenAI is going public as the worst value among its peers

Investors are paying a steep price relative to the underlying business quality, PitchBook research says.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,824.8067.500.77%
CAC 408,203.434.140.05%
DAX 4024,433.06183.16-0.74%
Dow JONES (US)50,872.1186.100.17%
FTSE 10010,227.33145.87-1.41%
HKSE24,565.9091.16-0.37%
NASDAQ25,678.82250.84-0.97%
Nikkei 22565,416.631,392.032.17%
NZX 50 Index13,163.1940.89-0.31%
S&P 5007,386.6519.08-0.26%
S&P/ASX 2008,604.2070.700.83%
SSE Composite Index4,010.0350.691.28%

Market Movers